MedDay's MD1003 study fails to reach primary endpoint

1 December 2015

A second placebo-controlled study of MD1003 in the treatment of progressive multiple sclerosis has failed to reach its primary endpoint, it has been revealed.

The MS-ON study, conducted by Paris, France-based biotech firm MedDay, was designed to investigate the superiority of MD1003, a highly-concentrated pharmaceutical-grade biotin administered at a dose of 300mg per day, over placebo in the visual improvement of patients suffering from chronic visual loss resulting from optic neuritis (MS-ON).

Patients who received MD1003 tended to improve slightly more than patients who received the placebo but the difference did not reach statistical significance.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK